Frequently Asked Questions
What is Regenerate℠?
Regenerate is a risk product that provides financial protection in the form of reinsurance coverage helping stop loss carriers to reduce the catastrophic costs of cell and gene therapy claims. Regenerate is supported by a panel of highly-rated, professional, domestic reinsurers.
Who can buy coverage through Regenerate?
Companies such as employer stop loss carriers, captives, HMO’s and self-funded MEWAs that assume risk from employer stop loss products.
What therapies are covered and how does Regenerate differ from other products on the market?
Covered therapies include cell and gene therapies currently approved by the United States Food and Drug Administration (FDA) and therapies on the cell and gene pipeline with FDA approval dates anticipated 15 months forward, updated quarterly. This coverage level makes this product more comprehensive than many other financial protections or risk products.
Why is reinsurance protection for cell and gene therapies so important?
The number of emerging therapies for rare conditions is increasing as are the costs for these treatments.
How can I learn more?
Contact the Regenerate team at info@regeneratere.com